Since SGLT2 inhibitors were previously reported to reduce body weight and improve glycemia, dyslipidemia and liver function [16,17,18], we divided the patients into two subgroups under the treatments with or without SGLT2 inhibitors and analyzed the changes in metabolic parameters during the 12-month dulaglutide treatment (Table 6). Here, SLC5A2 is linked to metabolic syndrome.